DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

被引:45
作者
Alexander, Brian M. [1 ]
Wang, Xiao Zhe [2 ,3 ]
Niemierko, Andrzej
Weaver, David T. [2 ,3 ]
Mak, Raymond H.
Roof, Kevin S. [6 ]
Fidias, Panagiotis [4 ]
Wain, John [5 ]
Choi, Noah C.
机构
[1] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] On Q Ity Inc, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] SE Radiat Oncol, Charlotte, NC USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 83卷 / 01期
关键词
Biomarkers; Chemoradiotherapy; DNA repair; Esophageal cancer; SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; CHEMOTHERAPY; EXPRESSION; CHEMORADIATION; DEFICIENCY; CISPLATIN; BENEFITS; HMLH1;
D O I
10.1016/j.ijrobp.2011.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The addition of neoadjuvant chemoradiotherapy prior to surgical resection for esophageal cancer has improved clinical outcomes in some trials. Pathologic complete response (pCR) following neoadjuvant therapy is associated with better clinical outcome in these patients, but only 22% to 40% of patients achieve pCR. Because both chemotherapy and radiotherapy act by inducing DNA damage, we analyzed proteins selected from multiple DNA repair pathways, using quantitative immunohistochemistry coupled with a digital pathology platform, as possible biomarkers of treatment response and clinical outcome. Methods and Materials: We identified 79 patients diagnosed with esophageal cancer between October 1994 and September 2002, with biopsy tissue available, who underwent neoadjuvant chemoradiotherapy prior to surgery at the Massachusetts General Hospital and used their archived, formalin-fixed, paraffin-embedded biopsy samples to create tissue microarrays (TMA). TMA sections were stained using antibodies against proteins in various DNA repair pathways including XPF, FANCD2, PAR, MLH1, PARP1, and phosphorylated MAPKAP kinase 2 (pMK2). Stained TMA slides were evaluated using machine-based image analysis, and scoring incorporated both the intensity and the quantity of positive tumor nuclei. Biomarker scores and clinical data were assessed for correlations with clinical outcome. Results: Higher scores for MLH1 (p = 0.018) and lower scores for FANCD2 (p = 0.037) were associated with pathologic response to neoadjuvant chemoradiation on multivariable analysis. Staining of MLH1, PARP1, XPF, and PAR was associated with recurrence-free survival, and staining of PARP1 and FANCD2 was associated with overall survival on multivariable analysis. Conclusions: DNA repair proteins analyzed by immunohistochemistry may be useful as predictive markers for response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. These results are hypothesis generating and need confirmation in an independent data set. (C) 2012 Elsevier Inc.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 21 条
[1]   DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer [J].
Alexander, Brian M. ;
Sprott, Kam ;
Farrow, D. Allan ;
Wang, XiaoZhe ;
D'Andrea, Alan D. ;
Schnitt, Stuart J. ;
Collins, Laura C. ;
Weaver, David T. ;
Garber, Judy E. .
CLINICAL CANCER RESEARCH, 2010, 16 (23) :5796-5804
[2]  
[Anonymous], 2002, AJCC CANC STAGING HD
[3]   Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: Mature results of phase II study [J].
Choi, NC ;
Park, SD ;
Lynch, T ;
Wright, C ;
Ancukiewicz, M ;
Wain, J ;
Donahue, D ;
Mathisen, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01) :111-122
[4]   The Fanconi anaemia BRCA pathway [J].
D'Andrea, AD ;
Grompe, M .
NATURE REVIEWS CANCER, 2003, 3 (01) :23-34
[5]   Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis [J].
Gebski, Val ;
Burmeister, Bryan ;
Smithers, B. Mark ;
Foo, Kerwyn ;
Zalcberg, John ;
Simes, John .
LANCET ONCOLOGY, 2007, 8 (03) :226-234
[6]  
Giaccia, 2006, RADIOBIOLOGY RADIOLO, VVol 6
[7]   A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer [J].
Graeser, Monika ;
McCarthy, Afshan ;
Lord, Christopher J. ;
Savage, Kay ;
Hills, Margaret ;
Salter, Janine ;
Orr, Nicholas ;
Parton, Marina ;
Smith, Ian E. ;
Reis-Filho, Jorge S. ;
Dowsett, Mitch ;
Ashworth, Alan ;
Turner, Nicholas C. .
CLINICAL CANCER RESEARCH, 2010, 16 (24) :6159-6168
[8]   DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes [J].
Kennedy, Richard D. ;
D'Andrea, Alan D. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) :3799-3808
[9]   Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase Cα [J].
Kerfoot, C ;
Huang, WD ;
Rotenberg, SA .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (03) :419-422
[10]  
Kishi K, 2003, CLIN CANCER RES, V9, P4368